Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1901-1920 of 2,251 trials

Lung Cancer Treatment: Immunotherapy and Radiation

We are studying a new treatment combining immunotherapy and radiation for elderly or unfit patients with advanced lung cancer. The aim is to see if this approach improves survival and quality of life.

Unresectable Stage III Non-Small Cell Lung Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Myeloma Treatment: Elranatamab vs. Daratumumab

We are studying whether elranatamab combined with lenalidomide helps patients with newly diagnosed myeloma maintain remission better than daratumumab with lenalidomide after a transplant. This trial will also assess safety and quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Bladder Cancer: V940 and BCG Combination Study

We are investigating whether a new treatment, V940, combined with BCG can improve outcomes for people with high-risk non-muscle invasive bladder cancer compared to BCG alone. This study will also assess the safety of all treatment options.

Bladder Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Rheumatoid Arthritis: CIT-013 Study

We are investigating a new medication, CIT-013, for people with moderately active rheumatoid arthritis. The study aims to see if it helps reduce disease activity and to understand its safety.

Moderately Active Rheumatoid Arthritis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

COVID-19 Vaccine Immunology Study in Finland

We are studying how different COVID-19 vaccines affect immune responses in various groups. This research may help us understand the need for boosters and how well vaccines work against different virus variants.

COVID-196-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Pancreatic Cancer: Hyperpolarized Pyruvate Imaging Study

We are testing a new imaging technique using hyperpolarized pyruvate in patients with pancreatic cancer. This study aims to confirm its safety and gather data to help improve future treatments.

Pancreatic Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Ovarian Cancer: Olaparib and Bevacizumab Study

We are studying how well a new test identifies genetic markers in patients with advanced ovarian cancer and whether combining Olaparib with Bevacizumab improves treatment outcomes. This trial aims to evaluate the safety and effectiveness of this drug combination.

Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Multiple Myeloma: New Treatment Combinations

We are studying a combination of new medications for people with newly diagnosed multiple myeloma who can undergo a transplant. The goal is to evaluate their safety and effectiveness in improving treatment outcomes.

Multiple MyelomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Metformin for Small Abdominal Aortic Aneurysms

We are studying if taking metformin daily can slow the growth of small abdominal aortic aneurysms in patients without diabetes. This trial also looks at the safety and quality of life for participants.

Small Abdominal Aortic Aneurysm>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

CD20-Positive Acute Lymphoblastic Leukemia: Obinutuzumab vs. Rituximab

We are comparing two treatments, obinutuzumab and rituximab, for adults with newly diagnosed CD20-positive acute lymphoblastic leukemia. The goal is to see which treatment helps more patients achieve complete remission safely.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Ovarian Cancer Relapse: Hyperthermic Intraperitoneal Chemotherapy Study

We are investigating whether adding HIPEC improves survival for patients with ovarian cancer relapse compared to standard treatment. The study also looks at quality of life, side effects, and other important factors.

Ovarian Epithelial Cancer Relapse>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Pancreas and Kidney Transplant: Sirolimus vs. Mycophenolate Mofetil

We are comparing two medications to see which one may reduce the risk of hernias after simultaneous pancreas and kidney transplants in people with type 1 diabetes. We also want to understand their effects on diabetes complications.

End-stage Kidney Disease in Type 1 DiabetesTransplantation ComplicationsSimultaneous Pancreas and Kidney Transplantation>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal MedicineNephrologyOncologyUrology

Dental Implants: Antibiotic Use in Bone Augmentation

We are studying whether short or long-term antibiotic use is more effective during dental implant surgery. This trial will also look at how these antibiotics affect bacteria in the mouth and gut.

Need for Oral Bone Augmentation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesOrthopedics and Traumatology

Heart Function in Cancer Patients: Nivolumab and Pembrolizumab

We are studying how immunotherapy treatments affect heart function in patients with cancer. This includes monitoring changes in heart performance and rhythm during treatment.

Cancer3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyOncology

Improving Ovarian Reserve: rhLH Treatment Study

We are investigating whether a hormone treatment can increase the number of healthy follicles in women trying to conceive. This study aims to assess its effects on fertility and overall safety.

Assisted Fertilization1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Sacubitril/Valsartan for Arrhythmogenic Right Ventricular Cardiomyopathy

We are studying whether sacubitril/valsartan can help prevent disease progression in patients with ARVC. This trial aims to assess its effects on heart tissue changes.

Arrhythmogenic Cardiomyopathy>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiology

Breast Cancer: Palbociclib and Fulvestrant Study

We are investigating if a new treatment combination can help prevent relapse in patients with ER positive HER2 negative breast cancer. This study focuses on those with detectable tumor DNA during treatment.

ER Positive HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

HER2 Mutated Solid Tumors: Sevabertinib Study

We are studying how well sevabertinib tablets work and their safety for patients with solid tumors that have HER2 mutations. This research may help improve treatment options for these patients.

Pancreatic CancerUrothelial CarcinomaGallbladder Cancer6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineOncology

Chronic Pain After Mastectomy: Comparing Treatments

We are studying the effectiveness of Serratus Plane Block, capsaicin, and botulinum toxin type A for managing chronic neuropathic pain after mastectomy. This trial aims to find out which treatment offers better pain relief for those not helped by standard therapies.

Post-Mastectomy Pain Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurologyOncology

Prostate Cancer: BMS-986365 vs. Standard Treatment

We are comparing a new medication, BMS-986365, to standard treatments for men with metastatic castration-resistant prostate cancer. The study aims to see if the new drug can better delay disease progression and improve overall health.

Metastatic Castration-resistant Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology